Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

New Sopheon Software Release

7 Apr 2022 07:00

RNS Number : 5540H
Sopheon PLC
07 April 2022
 

SOPHEON PLC

("Sopheon" or the "Company")

 

Sopheon Boosts Innovation System with Real-time Information and Collaboration Enhancements

Sopheon, the leading international provider of software and services for Enterprise Innovation Management solutions, today announced a series of upgrades to its flagship product, Accolade®.

 

With an unprecedented level of transparency resulting in better analysis, a higher level of risk identification and improved reporting, Accolade enables stakeholders to make faster, fact-based decisions that drive innovation forward.

Accolade is a flexible and scalable single innovation system that provides the ability to control and manage innovation and new product development programs more effectively. Hundreds of long-standing blue-chip customers have experienced superior strategy-to-execution performance, increased time to market, streamlined operational costs and greater product success.

 

"Innovation projects face many speed bumps on the road from inception to the market. Sopheon has smoothed the road to innovation success with these latest communication and collaboration enhancements," said Michael Bauer, chief product officer of Sopheon. "Accolade provides a secure, self-service environment that allows stakeholders to be self-reliant in tracking processes and progress. By staying informed on a real-time basis, without needing the involvement of project managers, key stakeholders are empowered to make faster, fact-based decisions. Sopheon's Accolade provides the perfect mix of self-reliance, accountability, transparency and decision-making capabilities for ensuring new product success."

 

Benefits of the latest Accolade enhancements include:

 

Real-time information sharing - Accolade provides an easy and secure way for project and portfolio managers to set up and share information. Stakeholders can see live data automatically on-demand without needing a license for Accolade. This provides visibility into product portfolio performance and ensures that stakeholders are completely informed and aligned with relevant information that is always up to date.

 

Deeper collaboration - The addition of Slack to Sopheon's support for Microsoft Teams extends Accolade's communication and collaboration capabilities. The improved and fully integrated experience enables users to easily engage team members where they are most comfortable working in Accolade.

 

Valuable new insights - Sopheon's Trended Metrics is a powerful evaluation tool that helps users determine whether their product or portfolio is on track. Accolade automatically highlights and shows how specific metrics are trending and gives users an immediate indication where problems are likely to occur. It also captures updates since previous communications with stakeholders.

 

For further information contact:

Andy Michuda (Executive Chairman)Arif Karimjee (CFO)

Sopheon plc

+ 44 (0) 1276 919 560

Carl Holmes/Edward Whiley (Corporate Finance)

Alice Lane (ECM)

finnCap

+ 44 (0) 20 7220 0500

 

Sopheon and Accolade are trademarks of Sopheon plc. All other trademarks are the property of their respective owners.

About Sopheon. Sopheon (LSE: SPE) partners with customers to provide complete enterprise innovation management solutions including software, expertise, and best practices, that enable them to achieve exceptional long-term revenue growth and profitability. Sopheon's Accolade solution provides unique, fully-integrated coverage for the entire innovation management and new product development lifecycle, including strategic innovation planning, roadmapping, idea and concept development, process and project management, portfolio management and resource planning. Sopheon's solutions have been implemented by over 200 customers with over 60,000 users in over 50 countries. Sopheon is listed on AIM, operated by the London Stock Exchange. For more information, please visit www.sopheon.com.  

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAELKEDSAEAA
Date   Source Headline
27th Jan 20117:00 amPRNTrading Statement
9th Dec 20107:00 amPRNAmendment to the Terms of Convertible Loan Stock
16th Nov 20107:00 amPRNContract Win
4th Nov 20107:00 amPRNInterim Management Statement
27th Aug 201010:30 amPRNGrant of Options
26th Aug 20107:00 amPRNHalf-yearly Report
22nd Jul 20107:00 amRNSTrading Update
15th Jun 20105:31 pmPRNResult of AGM
15th Jun 20107:00 amPRNAGM Statement
18th May 20107:00 amRNSAfton Chemical Selects Idea Lab
6th May 20107:00 amPRNInterim Management Statement
25th Mar 20107:00 amPRNFinal Results
22nd Mar 20107:00 amRNSiSUSTAINT Alliance Launched
3rd Feb 20107:00 amRNSSopheon Team wins TARDEC Contract
28th Jan 20107:00 amPRNTrading Update
24th Dec 20097:01 amRNSExtension of GEM Equity Line
2nd Dec 20097:00 amRNSVision Strategist Version 5.0 Launched
3rd Nov 20097:00 amPRNInterim Management Statement
2nd Oct 20093:43 pmPRNISSUE OF CONVERTIBLE LOAN STOCK
27th Aug 20097:00 amPRNHalf-yearly Report
16th Jun 200912:34 pmPRNResult of AGM
16th Jun 20097:00 amPRNAGM Statement
19th May 20097:00 amPRNProduct Launch
7th May 20097:00 amPRNInterim Management Statement
26th Mar 20097:00 amPRNFinal Results
18th Mar 20097:00 amRNSBostik Implements Sopheon's Accolade System
11th Mar 20097:00 amRNSContract Win
11th Feb 20097:00 amRNSEnhanced Version of Accolade? Launched
28th Jan 20097:00 amPRNTrading Update
21st Jan 20097:00 amRNSSopheon Partners with Maxsoft
4th Nov 20087:00 amPRNInterim Management Statement
28th Aug 20087:00 amPRNHalf-yearly Report
27th Jun 20083:47 pmPRNDirector/PDMR Shareholding
25th Jun 20087:00 amPRNGrowth Milestone
10th Jun 20087:00 amPRNAGM Statement
16th May 20087:00 amPRNDirector/PDMR Shareholding
15th May 20087:00 amPRNInterim Management Statement
6th May 200810:00 amPRNNotice of AGM
29th Apr 20087:02 amRNSContract Win
1st Apr 200810:00 amPRNGrant of Options
27th Mar 20087:00 amPRNFinal Results
6th Feb 20087:01 amRNSProduct Development
25th Jan 20087:00 amPRNTrading Update
21st Dec 200710:30 amPRNTrading Update
25th Oct 20077:00 amPRNTrading Update
16th Oct 20072:38 pmBUSBeiersdorf Implements Sopheon System in Support of Product Innovation Strategy
16th Oct 20077:01 amRNSContract Win
10th Oct 20072:45 pmBUSLeading European Center for Clinical Trials Research Selects Sopheon's Accolade(R) System
10th Oct 20077:01 amRNSContract Win
1st Oct 20077:02 amRNSContract Win

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.